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Amélioration dans l’obtention d’anticorps du jaune d’œuf (IgY) spécifiques d’un antigène et destinés à l’immunisation 
passive par voie alimentaire chez l’animal (synthèse bibliographique). Les	anticorps	sont	devenus	au	fil	des	années	des	









Hens’	 eggs	 have	 long	 been	 known	 as	 an	 excellent	
source	 of	 nutrients	 for	 humans.	 They	 are	 also	 an	
important	 source	 of	 antibodies,	 the	 most	 abundant	
being	 immunoglobulin	 (Ig)	Y.	This	 characteristic	 has	
attracted	increasing	interest	in	recent	decades	(Yegani	
et	 al.,	 2010).	 The	 natural	 transfer	 of	 antibodies	 that	
occurs	 from	 hen	 to	 chick	 via	 the	 egg	 yolk	 can	 be	
exploited	 to	 produce	 antibodies	 specific	 to	 a	 given	
pathogen,	simply	by	immunizing	the	laying	hens	with	
an	antigen	from	this	targeted	pathogen	(Kovacs-Nolan	






and	 others,	 thanks	 to	 its	 ability	 to	 produce	 massive	
amounts	 of	 antibodies	 specific	 to	 targeted	 bacteria.	
These	 antibodies	 could	 help	 address	 the	 worldwide	
emergence	 of	 drug-resistant	 microorganisms	 and	 the	
resultant	 reduction	 in	 antibiotic	 use	 in	 the	 livestock	
industry.	 They	 also	 offer	 a	 solution	 to	 the	 inability	
to	 treat	 or	 prevent	 some	 diseases	 with	 conventional	
vaccines	 in	 some	 production	 sectors,	 such	 as	 in	
industrial	 broiler	 chickens	 whose	 lifespan	 is	 limited	
(about	42	days)	(Namata	et	al.,	2009).	Apart	from	the	
control	 of	 pathogens,	 hen	 egg	 yolk	 antibodies	 could	
also	 be	 used	 to	 modulate	 normal	 gut	 microflora,	 as	
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described	in	recent	ruminant	studies	in	order	to	control	
ruminal	fermentations	(Marino	et	al.,	2011).
Currently,	 these	 antibodies	 remain	 underused	 in	
both	 veterinary	 and	 human	 medicine.	 This	 review	
focuses	on	the	development	of	hen	egg	yolk	antibodies	
for	 the	 therapy	 and	 prophylaxis	 of	 animal	 diseases.	









2. THE PASSIVE IMMUNIZATION CONCEPT
Passive	immunization	involves	transferring	preformed	
antibodies	 from	 one	 individual	 to	 another,	 unlike	
active	immunization	where	an	animal	has	 to	produce	
its	 own	 antibodies.	 The	 best-known	 form	 of	 passive	
immunization	 is	 the	 transfer	 of	 maternal	 antibodies	
from	 a	 mother	 to	 her	 descendants.	 In	 mammals,	 it	
occurs	 through	 colostrum	 ingestion	 and/or	 placental	
transfer;	 in	birds,	all	 the	antibodies	needed	to	protect	
the	 offspring	 are	 transmitted	 via	 the	 egg	 (Brambell,	
1970).	
Three	 immunoglobulin	 classes	 are	 deposited	
into	 the	 egg:	 IgA,	 IgM,	 and	 IgY.	Maternal	 IgA	 and	
IgM	 are	 present	 at	 low	 concentrations	 (0.7	 and	




As	 the	 adaptive	 immune	 system	 develops	 during	
the	first	2	weeks	post-hatch,	early	humoral	protection	
in	 the	 chick	 depends	 heavily	 upon	 this	 maternal	
transfer	 (Smith	 et	 al.,	 2008).	The	given	protection	 is	
efficient,	but	it	is	short-term	and	is	limited	to	infections	
present	 in	 the	 hen’s	 environment	 at	 the	 time	 of	 lay	
(Smith	et	al.,	2008).	Nevertheless,	it	is	possible	to	take	
advantage	 of	 this	 natural	 transfer	 of	 antibodies	 from	
hen	 to	 chick.	The	 concentration	 of	 IgY	 deposited	 in	
the	egg	is	closely	linked	to	that	in	the	maternal	serum	
(Hamal	et	al.,	2006).	Therefore,	by	immunizing	laying	
hens	 with	 a	 specific	 target	 antigen,	 we	 can	 manage	
their	immune	system	and	the	composition	of	the	pool	
of	antibodies,	first	in	the	serum,	then	in	the	eggs.	The	
specific	 antibodies	obtained	 can	 then	be	 exploited	 to	
immunize	 other	 individuals	 via	 a	 feed	 additive	 (Xu	




3. ADVANTAGES OF IGY TECHNOLOGY
The	 growing	 interest	 in	 IgY	 technology	 stems	 from	




This	 is	 in	complete	accordance	with	 the	principle	of	




Methods	 (Schade	 et	 al.,	 1996).	 It	 is	 a	 refinement	 of	
the	 antibody	 production	 protocol	 because	 it	 does	
not	 involve	bleeding	 the	antibody	producer	animals,	
unlike	 the	mammals	models.	 The	 long-lasting	 titers	
obtained	 from	 laying	 hens	 also	 reduce	 the	 need	 for	
frequent	 booster	 injections	 (Schade	 et	 al.,	 2005).	
Another	 advantage	 is	 that	 laying	 hens	 are	 able	 to	





so	 because	 the	 cost	 of	 feeding	 and	 housing	 laying	
hens	 tends	 to	 be	 lower	 than	 for	 mammals.	 The	
numerous	 IgY	 extraction	 processes	 described	 in	 the	
literature	 (De	Meulenaer	 et	 al.,	 2001)	 are	 usually	
both	 efficient	 and	 cheap.	 The	 hyper-immune	 yolk	
can	also	be	used	 just	as	 it	 is,	as	discussed	 later.	The	




attractive	 because	 of	 its	 high	 specificity	 compared	
with	other	alternatives	to	antibiotics,	such	as	organic	




the	 case	 of	 polyclonal	 egg	 yolk	 antibodies.	 When	
Chalghoumi	 et	 al.	 (2008)	 developed	 IgY	 specific	 to	
two	 Salmonella	 serovars,	 they	 demonstrated	 a	 high	
level	 of	 cross-reactivity	 of	 IgY	 developed	 against	 a	
particular	 serovar	 with	 antigens	 of	 the	 other	 one,	
and	 vice versa.	 Thus,	 using	 vaccine	 antigens	 shared	
among	 several	 serovars	 addresses	 the	 risk	 of	 the	
developed	IgY	being	too	highly	specific.	In	addition,	
the	 fact	 that	 Chalghoumi	 et	 al.	 (2008)	were	 able	 to	
raise	IgY	against	two	Salmonella	serovars	in	a	single	
egg	 yolk	 indicates	 that	 it	 could	 soon	 be	 possible	 to	
develop	 real	 “cocktail	 eggs”	 targeting	 a	 diverse	 set	





4. STANDARD PROTOCOLS FOR IGY 
PRODUCTION
The	 standard	 protocol	 for	 producing	 antigen-specific	
IgY	 intended	 for	 passive	 dietary	 immunization	 in	
animals	is	illustrated	in	figure 1.	





immune	 response	 has	 been	 induced,	 the	 transovarial	





some	authors	 reporting	yolk	 titers	higher	 than	 serum	
titers,	and	vice versa	(Woolley	et	al.,	1995;	Malik	et	al.,	
2006).	These	inconsistent	data	could	be	explained,	at	
least	partly,	by	 the	biological	oscillations	 in	 egg	 IgY	




an	 antigen-adjuvant	 combination	 at	 certain	 intervals.	
Numerous	 protocols,	 using	 different	 antigens,	
adjuvants,	 injection	 routes	 and	 intervals	 between	
injections,	 have	 been	 described	 over	 the	 years.	 All	
these	 factors	 are	 critical	 because	 they	 influence	 both	
the	outcome	of	 the	 immunization	procedure	 (amount	
and	 specificity	 of	 the	 obtained	 IgY)	 and	 the	welfare	





The	first	 step	 in	specific	 IgY	production	 is	 to	choose	
the	target	antigen.	This	can	be	a	single	antigen	(protein,	
peptides	 or	 polysaccharides)	 or	 a	 complex	 multi-
antigen	(bacteria,	mold,	viruses	or	parts	of	these).	The	
molecules	 exhibiting	 the	 best	 immunogenicity	 are	
proteins	(Schwarzkopf	et	al.,	2001).	In	the	case	of	small	
antigens	 with	 a	 molecular	 weight	 below	 12,000	da	
(known	as	“haptens”),	conjugation	to	a	carrier	protein	
(e.g.,	bovine	gamma	globulin)	is	often	required	(Cook	
et	 al.,	 2010).	 Carbohydrates	 and	 nucleic	 acids	 could	
also	be	coupled	advantageously	with	carriers	because	
of	their	reduced	immunogenicity	(Schwarzkopf	et	al.,	
2001).	 Apart	 from	 the	 intrinsic	 immunogenicity	 of	
the	target	antigen,	its	quality	and	quantity	should	also	
be	 taken	 into	 account.	The	purity	 of	 the	 antigen	 is	 a	
crucial	parameter	because	impurities	could	lead	to	IgY	
with	more	 activity	 against	 the	 impurities	 themselves	
than	 against	 the	 antigen	 of	 interest	 (Leenaars	 et	 al.,	
2005).	In	addition,	contaminations	of	the	antigen	with	
microbes,	 endotoxins	 or	 chemical	 residues	 from	 the	
inactivation/extraction	process	 could	have	 a	 negative	
effect	 on	 animal	 welfare	 as	 well	 as	 on	 immune	
response	 (Leenaars	et	al.,	2005).	The	antigen	dose	 is	
also	critical	because	too	much	or	too	little	antigen	can	
lead	 to	 suppression,	 sensitization,	 tolerance	 or	 other	
undesirable	immunomodulatory	effects	(Schwarzkopf	





The	 aqueous	 portion	 of	 the	 vaccine	 dose	 is	 diluted	
in	 a	 physiological	 saline	 solution	 and	 the	 antigen	
solution	 thus	 obtained	 is	 commonly	 combined	 with	
an	adjuvant	to	ensure	effective	immune	response.	The	
induced	response	can	be	more	cellular	 than	humoral,	
or	 vice versa,	 depending	 on	 the	 chosen	 adjuvant.	 In	
the	case	of	antibody	production,	the	humoral	response	
should	be	favored.	There	are	dozens	of	commercially	
available	 adjuvants	 that	 have	 been	 described	 in	
reviews	(e.g.	Stills,	2005;	Wilson-Welder	et	al.,	2009).	
Among	 these	multiple	 adjuvants,	 Freund’s	 adjuvants	
(FA)	 remain	 the	 “gold	 standard”	 and	 are	 widely	
used	 for	 experimental	 antibody	 production.	 Freund’s	
complete	 adjuvant	 (FCA)	 is	 the	 most	 effective	 in	
terms	 of	 productivity;	 it	 has	 not	 been	 surpassed	 by	
any	adjuvant	(Stills,	2005).	FCA	has	been	associated,	
however,	 with	 a	 variety	 of	 undesirable	 side	 effects,	
particularly	 in	mammals.	These	 findings	 have	 led	 to	
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Figure 1.	 Standard	 protocol	 for	 the	 production,	 in	 laying	
hens,	 of	 antigen-specific	 IgY	 intended	 for	 passive	 dietary	
immunization	 in	 animals	 (adapted	 from	 Kim	 et	 al.,	
2000)	—	Protocole standard relatif à la production, chez la 
poule pondeuse, d’IgY spécifiques d’un antigène et destiné 
à l’immunisation passive par voie alimentaire chez l’animal 
(adapté de Kim et al., 2000).
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numerous	regulatory	guidelines	controlling	the	use	of	
FCA	in	experimental	animals.	Nevertheless,	it	is	worth	
noting	 that	 FCA	 is	 less	 problematic	 in	 birds	 (Bollen	
et	 al.,	 1996;	Chalghoumi	 et	 al.,	 2008),	 although	 this	




used	 for	 laying	hens	 (mainly	 intramuscular,	 see	4.3.)	
might	hide	 the	 resulting	 local	 inflammation,	whereas	
other	 injection	 routes	 (subcutaneous	 or	 intradermal)	
used	more	frequently	in	mammals	might	facilitate	the	
observation	 of	 the	 tissue	 reaction.	 The	 most	 recent	
findings	 in	 our	 laboratory	 (data	 to	 be	 published)	
corroborate	 this	 argument.	 The	 second	 factor	 is	 the	
quality	of	emulsion.	Even	 in	mammals,	 it	 seems	 that	
FCA	is	not	as	damaging	as	previously	reported,	at	least	
when	 a	 limited	 volume	 of	 high-quality	 emulsion	 is	
injected	(Leenaars	et	al.,	2005).	At	the	laboratory	level,	
we	 advise	 following	 the	 “T”-connector	 emulsifying	
protocol	 proposed	 by	Moncada	 et	 al.	 (1993),	 where	
the	 final	 vaccine	 emulsion	 is	 obtained	 by	 repeated	
passages	of	the	adjuvant	and	antigen	mixture	through	








use	 of	 FIA	 is	 sometimes	 recommended	 even	 for	 the	
first	immunization	(Narat,	2003).	
4.3. Injection route 
The	 vaccine	 is	 usually	 injected	 through	 the	
intramuscular	route,	most	often	in	the	pectoralis major	
muscle	(Schade	et	al.,	2005).	The	subcutaneous	route	
has	 also	 been	 used	 (Mayo	 et	 al.,	 2009;	Lakeh	 et	 al.,	
Table 1. Recommendations	 on	 laying	 hen	 immunization	 for	 IgY	 production	 purposes	with	 regard	 to	 animal	welfare	—














































considerations	 (Schade	 et	 al.,	 1996).	 In	 addition,	
the	 intramuscular	 route	 results	 in	 levels	 of	 specific	
IgY	 nearly	 10	times	 higher	 than	 in	 the	 case	 of	 the	
subcutaneous	 route	 (Chang	et	al.,	1999).	 In	 terms	of	
animal	welfare,	 it	 is	 imperative	 to	 limit	 the	 quantity	
injected	 to	 that	 which	 is	 sufficient	 to	 induce	 the	
antibody	 response,	 without	 exceeding	 the	 maximal	
volume	of	1	ml	and	a	maximum	of	four	injection	sites	
(Leenaars	et	al.,	2005).
4.4. Immunization schedule 
Immunization	should	be	performed	when	the	animals	





Booster	 injections	 are	 needed	 in	 order	 to	 take	





the	 adjuvant	 used.	The	 general	 rule	 is	 to	 administer	
a	booster	 immunization	when	 the	IgY	titer	 reaches	a	
plateau	or	begins	to	decrease	(Leenaars	et	al.,	2005).	






can	 begin	 as	 early	 as	 1	week	 after	 the	first	 injection	
(Bollen	et	al.,	1997),	but	 the	IgY	titer	peak	has	been	
reported	 from	 3	weeks	 after	 the	 first	 immunization	
(Trott	et	al.,	2008)	to	2	weeks	after	the	second	booster	
injection	(Schade	et	al.,	2005).
4.5. Extraction and processing of IgY 
The	extraction	of	 IgY	 from	 the	egg	can	be	achieved	
using	 several	methods,	 resulting	 in	 variations	 in	 the	
recovery	 and	purity	 of	 the	 extract.	Usually,	 the	 yolk	
is	separated	from	the	white,	but	sometimes	the	whole	
egg	 is	 used	 as	 a	 feed	 additive	 (Gürtler	 et	 al.,	 2004).	
The	antibodies	can	then	be	purified,	from	completely	
purified	 IgY	 to	 unpurified	 whole	 yolk	 options.	 The	
choice	of	IgY	extraction	method	is	influenced	mainly	
by	 the	 required	 purity	 of	 antibodies	 versus	 the	 cost	
effectiveness	 of	 the	 method.	 A	 number	 of	 methods	
of	 extracting	 IgY	 involving	 various	 chemicals	 have	
been	described	(for	a	review	of	current	protocols,	see	
De	Meulenaer	et	al.,	2001).	Each	method	has	specific	
purposes	 and	 it	 is	 almost	 impossible	 to	 provide	
a	 recommendation	 for	 each	 of	 the	 many	 possible	
applications	 of	 IgY.	 Some	 general	 recommendations	
are	 provided,	 however,	 in	 table 2	 as	 a	 first	 line	 of	
approach.	 Usually,	 eggs	 used	 for	 laboratory	 reagent	
production	are	purified,	whereas	eggs	used	in	animal	
experiments	 are	 used	 as	 whole	 yolk	 (Cook	 et	 al.,	
2010),	 which	 has	 economic	 advantages.	 Indeed,	 the	
commercial	 IgY	 purification	 kits	 available	 on	 the	
market	are	still	expensive	(Tan	et	al.,	2012).	The	whole	
yolk	option	allows	one	to	take	advantage	of	other	egg	
yolk	 components	 that	 have	 also	 been	 suggested	 as	
protective,	such	as	high-density	lipoproteins	(Kassaify	
et	 al.,	 2005)	 or	 sialyloligosaccharides	 and	 their	
derivatives	(Sugita-Konishi	et	al.,	2002).	The	obtained	




some	have	used	a	 liquid	 form	 (Rahimi	 et	 al.,	 2007).	
IgY	could	possibly	be	provided	in ovo	(Yegani	et	al.,	
2010),	but	higher	mortality,	 reduced	hatchability	and	
reduced	 growth	 of	 chicks	 have	 been	 reported	 using	
this	approach	(Eterradossi	et	al.,	1997).	
Table 2.	Recommendations	on	extraction-purification	methods	depending	on	the	subsequent	use	of	IgY	—	Recommandations 
quant aux méthodes d’extraction-purification des IgY en fonction de leur usage subséquent.
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method	 used	 alongside	 the	 extraction	 process	 has	 a	
great	influence	on	the	yield	recovered	(Tan	et	al.,	2012).	
Within	the	total	amount	of	IgY	obtained,	an	average	of	
9%	can	be	 expected	 to	 be	 antigen-specific	 (Li	 et	 al.,	
1998).	 These	 yields	 are	 certainly	 impressive,	 but	 an	
improvement	in	the	percentage	of	antigen-specific	IgY	
in	the	eggs	and	a	reduction	in	the	time	needed	to	reach	




highly	 specific	 antibodies,	 welfare	 issues	 cannot	 be	
neglected.	 These	 issues	 already	 play	 an	 important	
role	in	the	way	researchers	design	their	immunization	
protocols,	and	this	is	expected	to	increase.	
There	 are	 several	 variation	 parameters	 for	
optimizing	 the	 IgY	 production	 protocol	 in	 terms	 of	
both	 yield	 and	 welfare.	 On	 the	 one	 hand,	 the	 focus	
can	be	on	 the	vaccine;	on	 the	other,	 it	 can	be	on	 the	
producer	animal	itself.	





lines.	 Nevertheless,	 for	 Cook	 et	 al.	 (2010),	 there	 is	
very	little	difference	in	the	ability	of	commercial	lines	
to	 produce	 antibodies,	 the	most	 important	 parameter	
governing	 the	 production	 of	 IgY	 over	 a	 year	 being	
egg	 size	 and	 rate	of	 lay.	 IgY	concentration	 (mg.ml-1)	
in	 the	 yolk	 is	 independent	 of	 the	 rate	 of	 lay	 or	 egg	
size	(Li	et	al.,	1998;	Trott	et	al.,	2009;	Ulmer-Franco	
et	al.,	2012).	Hence,	a	larger	egg	yolk	leads	to	a	higher	
amount	 of	 antibody	per	 egg.	The	 productivity	 of	 the	
line	 is	 therefore	 the	 key	 parameter	 to	 consider	when	




The	 production	 period	 can	 be	 extended	 for	 a	
second	year	because	an	interruption	during	the	lay	or	
the	practice	of	molting	hens	before	or	after	 initiating	
antibody	 production	 has	 little	 or	 no	 impact	 on	 the	
collected	level	of	IgY	(Pauly	et	al.,	2009;	Trott	et	al.,	
2009).	 In	 contrast,	 egg	 yolk	 weight	 increases	 with	
flock	age,	thus	increasing	the	amount	of	IgY	recovered	
(Pauly	et	al.,	2009;	Ulmer-Franco	et	al.,	2012).	Pauly	










responsiveness	 (Leandro	 et	 al.,	 2011).	 Therefore,	




to	 IgY	 technology	 because	 the	 association	 of	 hens	
and	 laid	 eggs	 is	 easier	with	 conventional	 cages	 than	
in	 free-range	 or	 coop	 systems.	 In	 mass	 production,	
however,	 where	 immunization	 protocols	 are	 already	










Maximizing	 IgY	 deposition	 seems	 to	 be	 achieved	
mainly	 by	 optimizing	 vaccination	 procedures.	 The	
most	critical	point	 is	 the	composition	of	 the	vaccine,	
particularly	the	choice	of	adjuvant	added	to	the	antigen	
to	enhance	the	immune	response.	
Vaccine composition. Although	 FA	 are	 still	 used	
as	 standard	 adjuvants	 in	 laying	hens,	 it	 is	 likely	 that	
alternatives	will	be	used	to	a	greater	extent	in	the	future	
because	 of	 animal	 welfare	 considerations.	 FA	 are	
judged	 to	be	potentially	 toxic	and	 their	use	has	been	




specific	 IgY	 to	 be	 obtained	 from	 the	 eggs	 without	
leading	to	undesirable	side	effects.
Various	 alternatives	 have	 been	 evaluated	 in	
birds,	 including	 aluminum	 salts	 (de	 Paula	 et	 al.,	
2011),	 carbopol	 formulations	 (Kim	 et	 al.,	 2012),	 the	








2010)	 and	 DNA-based	 formulations	 (Loots	 et	 al.,	
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2006).	Many	 claim	 to	be	 less	 damaging	 and	painful	
than	 FCA,	 but	 none	 has	 been	 shown,	 so	 far	 as	 we	
know,	to	surpass	FCA	in	terms	of	antibody	response.	
Apart	 from	 the	 choice	 of	 an	 alternate	 adjuvant,	
the	 addition	 of	 immunostimulating	 components	 to	
a	 vaccine	 can	 markedly	 increase	 IgY	 deposition	 in	
the	 egg	 yolk.	 Table 3	 gives	 an	 overview	 of	 some	
promising	products	that	appear	to	achieve	this.	
The	 resulting	 enhancement	 of	 these	 additions	 is	
variable.	Lévesque	et	al.	(2007)	demonstrated	that	the	
supplementation	 of	 FIA	 with	 oligodeoxynucleotides	
(ODN)	 containing	 C-phosphate-guanosine	 motifs	





CpG-ODN	 is	 a	 very	 promising	 way	 of	 improving	
the	 immune	 response	 of	 immunized	 animals.	 The	
activity	 of	 CpG-ODN	 is	 motif-dependent	 and	 the	
CpG	sequences	that	stimulate	optimal	responses	differ	
among	 species	 (Rankin	 et	 al.,	 2001).	The	GTCGTT	
sequence	is	recognized	as	most	active	in	avian	species	
(Lévesque	 et	 al.,	 2007;	 Linghua	 et	 al.,	 2007).	 A	
phosphorothioate	backbone	renders	CpG-ODN	stable	
against	nucleases	and	allows	the	use	of	smaller	amounts	




motifs	 mimic	 the	 immunostimulatory	 effect	 of	 the	
bacterial	 DNA	 (Klinman	 et	 al.,	 2004).	 The	 addition	
of	killed	whole	cell	has	also	been	shown	to	improve	
humoral	 immune	 response	 in	 chickens	 (Trott	 et	 al.,	
2008).	 Trott	 et	 al.	 (2008)	 investigated	 the	 effect	 of	
adding	 various	 commercial	 bacterins	 to	 FCA	on	 the	
antibody	response	of	laying	hens	to	a	protein	antigen.	
The	 addition	 of	 Gram+	 Staphylococcus aureus	 or	
Streptococcus suis	to	FCA	increased	the	IgY	response.	
In	 contrast,	 Gram-	 Escherichia coli killed	 whole	
cells	 reduced	 the	 resulting	 antibody	 titer	 compared	
with	 that	observed	 for	FCA	alone.	Producers	of	 IgY	
should	 therefore	be	aware	 that	components	added	 to	
vaccines	do	not	always	improve	the	response,	but	can	
sometimes	reduce	it	(Trott	et	al.,	2008).
Recently,	 the	 enzyme	 lumazine	 synthase	 from	
Brucella	 spp.	 has	 been	 reported	 to	 increase	 IgY	
production	 in	 laying	 hens	 when	 fused	 to	 the	 target	
antigen	 (Bellido	 et	 al.,	 2012).	 Another	 recent	
study	 (Freitas	 et	 al.,	 2011)	 dealt	 with	 the	 potential	
immunostimulatory	 effect	 of	 propolis,	 and	 reported	
a	 dose-dependent	 response	 of	 IgY	 level	 in	 blood	
serum	 following	 the	 intra-abdominal	 administration	
of	an	ethanolic	extract	of	propolis	prior	to	intravenous	
vaccination.	
Such	 supplementation	 allows	 a	 reduction	 in	 the	
amount	 of	 antigen	 and/or	 the	 necessary	 amount	
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overall	cost-efficiency	of	the	vaccination.	In	addition,	
these	supplementations	can	also	improve	the	efficiency	
of	 an	 adjuvant	 that	 would	 be	 intrinsically	 less	
efficient	than	the	FA	but	could	compete,	thanks	to	the	
supplementation,	with	 a	 reduced	 risk	 of	 undesirable	
side	effects.
The	 suppression	 of	 the	 adjuvant	 could	 even	 be	
envisaged	when	 injecting	potent	 immunostimulatory	




course	 is	 to	 reduce	 only	 the	 adjuvant/antigen	 ratio,	
moving	from	a	conventional	50/50	(v/v)	ratio	to	30/70,	
for	example.
Alternative immunization routes.	 Classic	
immunization	 protocols	 involve	 injection,	 but	 oral	
routes	 have	 been	 proposed	 (voluntary	 intake	 or	






protocols	 is	still	 in	 its	 infancy	and	 they	need	further	
refinement	 if	 they	 are	 to	 compete	 with	 parenteral	
immunization	 protocols	 (Mayo	 et	 al.,	 2009).	As	 for	
the	 classic	 protocol,	 the	 outcome	 of	 immunization	
through	 the	 oral	 route	 could	 be	 enhanced	 via	
immunostimulating	 components.	 For	 example,	 the	
oral	 administration	 of	 CpG-ODN	 has	 been	 tested,	
but	exhibited	only	a	slight	and	temporary	increase	of	
serum	IgY	titer	in	broilers	(Ameiss	et	al.,	2006).	Such	
oral	 supplementation	 for	 enhancing	 IgY	 production	
needs	further	research.	
In	 the	 particular	 case	 of	 DNA	 vaccines,	 various	
methods	 have	 been	 used	 to	 improve	 their	 delivery	
and	immunogenicity.	Among	these	is	the	“gene	gun”	
method,	 which	 has	 recently	 gained	 more	 attention	
for	 birds’	 immunization	 (Niederstadt	 et	 al.,	 2012).	
Developed	 in	 the	 early	1980s,	 it	 involves	delivering	
DNA	or	RNA	coated	in	microscopic	gold	or	titanium	
particles	into	living	tissues.	This	immunization	route	
might	 lead	 to	 enhanced	 antibody	 titers,	 allowing	 a	
wider	use	of	DNA	vaccination	in	birds	in	the	future.	
DNA	vaccines	 still	 suffer	 from	poor	 cost	 efficiency,	






worth	noting	 that	 recent	work	on	mice	suggests	 that	
gene	 guns	 might	 also	 successfully	 deliver	 protein	
antigens	(Scheiblhofer	et	al.,	2013).	
Nutrition and immunomodulation.	 If	 nutrition	
affects	antibody	production	and	the	transfer	of	immunity	
to	 chicks	 (Leandro	 et	 al.,	 2011),	 supplementing	 the	
diet	could	also	be	considered	as	a	way	to	promote	IgY	
production.	 For	 example,	 the	 hydroxylated	 form	 of	
vitamin	 D
3
,	 25-hydroxycholecalciferol	 increased	 the	
level	of	IgY	in	the	serum	of	Salmonella	typhimurium-
challenged	 chickens	 (Chou	 et	 al.,	 2009).	 Dietary	
L-carnitine	 (β-OH-(γ-N-trimethylamino)-butyrate)	
supplementation	 (100	mg.kg-1)	 has	 been	 shown	 to	
enhance	 antigen-specific	 IgY	 in	 vaccinated	 broilers	
(Mast	 et	 al.,	 2000).	 The	 level	 of	 supplementation,	
however,	can	have	a	strong	influence	on	the	outcome	
of	 these	 immunomodulation	 trials;	 de	 Beer	 et	 al.	
(2009)	did	not	measure	any	increase	in	total	IgY	level	
in	 egg	 yolks	 following	 the	 addition	 of	L-carnitine	 at	
50	mg.kg-1	to	the	diet	of	broiler	breeder	hens.	A	“more	
is	 better”	 approach	 cannot	 be	 viewed	 as	 a	 panacea	
when	using	nutrition	to	modulate	immunity,	as	recently	
discussed	 by	 Korver	 (2012)	 using	 the	 example	 of	
vitamin	E,	 which	 could	 improve	 immune	 response	
but	 could	 also	 become	 immunosuppressive	 if	 there	
is	 excessive	 supplementation.	 Diet	 supplementation	





future	 in	 a	 wide	 range	 of	 applications,	 from	 human	
and	 veterinary	medicine	 to	 diagnostics	 and	 research.	
The	 generation	 of	 these	 antibodies	 via	 laying	 hens	
represents	 a	 reduction	 and	 refinement	 in	 animal	 use	
compared	with	the	conventional	methods	for	obtaining	
Ig	 via	 mammals.	 This	 technology	 could	 be	 further	
refined	 thanks	 to	 recent	 progress	made	 in	 adjuvantal	
methods	 as	 well	 as	 other	 approaches,	 such	 as	 oral	
immunization	 and	 nutritional	 immunomodulation.	
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